NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer

被引：0

作者：

Fehrenbacher, Louis

Jeong, Jong-Hyeon

Rastogi, Priya

Geyer, Charles E.

Paik, Soonmyung

Ganz, Patricia A.

Land, Stephanie R.

Costantino, Joseph P.

Swain, Sandra M.

Mamounas, Eleftherios P.

Wolmark, Norman

机构：

[1] Natl Surg Adjuvant Breast & Bowel Project, Vallejo, CA USA

[2] Kaiser Permanente Calif, Vallejo, CA USA

[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA

[4] NSABP, Pittsburgh, PA USA

[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[6] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA

[8] NSABP Biostat Ctr, Pittsburgh, PA USA

[9] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Natl Surg Adjuvant Breast & Bowel Project,Biostat, Pittsburgh, PA 15261 USA

[10] NSABP, Washington, DC USA

[11] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA

[12] MD Anderson Canc Ctr Orlando, Orlando, FL USA

[13] Allegheny Gen Hosp, Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA 15212 USA

[14] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS1139

引用

页数：1

共 50 条

[31] A phase III adjuvant trial of sequenced EC plus filgrastim plus epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)
Burnell, M. J.
Levine, M. N.
Chapman, J. A.
Bramwell, V.
Vandenberg, T.
Chalchal, H. I.
Albain, K.
Perez, E.
Rugo, H.
Pritchard, K.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[32] Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry
Sparano, J. A.
Gray, R. J.
Makower, D. F.
Pritchard, K. I.
Albain, K. S.
Hayes, D. F.
Geyer, C. E., Jr.
Dees, E. C.
Perez, E. A.
Olson, J. A., Jr.
Zujweski, J.
Keane, M. M.
Moreno, H. L. Gomez
Reddi, R. P.
Goggins, T. F.
Mayer, I. A.
Brufsky, A. M.
Toppmeyer, D. L.
Kaklamani, V. G.
Atkins, J. N.
Berenberg, J. L.
Sledge, G. W., Jr.
CANCER RESEARCH, 2016, 76
[33] Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study
Au, Heather-Jane
Eiermann, Wolfgang
Robert, Nicholas J.
Pienkowski, Tadeusz
Crown, John
Martin, Miguel
Pawlicki, Marek
Chan, Arlene
Mackey, John
Glaspy, John
Pinter, Tamas
Liu, Mei-Ching
Fornander, Tommy
Sehdev, Sandeep
Ferrero, Jean-Marc
Bee, Valerie
Santana, Maria J.
Miller, Dave P.
Lalla, Deepa
Slamon, Dennis J.
ONCOLOGIST, 2013, 18 (07): : 812 - 818
[34] T1b with ER negative, HER2-positive, and node-negative breast cancer patients might get benefit from adjuvant chemotherapy
Altundag, Kadri
JOURNAL OF BUON, 2020, 25 (05): : 2529 - 2530
[35] Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer
Heidemann, E
STRAHLENTHERAPIE UND ONKOLOGIE, 1998, 174 (05) : 290 - 291
[36] TBCRC-053: PRAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer
Connolly, Joseph J.
Spring, Laura M.
Taghian, Alphonse G.
Gadd, Michele
Warren, Laura
Garrido-Castro, Ana C.
King, Tari
Mittendorf, Elizabeth A.
Leone, Jose P.
Casey, Dana L.
Carey, Lisa
Traina, Tiffany A.
Abdou, Yara
Khan, Atif
Plitas, George
Wright, Jean
Santa-Maria, Cesar Augusto
Jacobs, Lisa
Blitzblau, Rachel
Hwang, E. Shelley
Anders, Carey
Krop, Ian
Wolff, Antonio C.
Thompson, Alastair M.
Denault, Elyssa
Gupta, Gaorav
Ho, Alice
CANCER RESEARCH, 2023, 83 (05)
[37] Upregulation of HER-2/neu by ovarian ablation:: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients
Lüftner, D
Jung, A
Schmid, P
Geppert, R
Kienle, E
Wernecke, KD
Possinger, K
BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 (03) : 245 - 255
[38] Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients
D. Lüftner
A. Jung
P. Schmid
R. Geppert
E. Kienle
K.D. Wernecke
K. Possinger
Breast Cancer Research and Treatment, 2003, 80 : 245 - 255
[39] Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry
Sparano, J.
Gray, R.
Zujewski, J. A.
Makower, D.
Pritchard, K.
Albain, K.
Hayes, D.
Geyer, C.
Dees, C.
Perez, E.
Keane, M.
Vallejos, C.
Goggins, T.
Mayer, I.
Brufsky, A.
Toppmeyer, D.
Kaklamani, V.
Atkins, J.
Olson, J.
Sledge, G.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S714 - S714
[40] The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
Eiermann, W.
Rezai, M.
Kuemmel, S.
Kuehn, T.
Warm, M.
Friedrichs, K.
Schneeweiss, A.
Markmann, S.
Eggemann, H.
Hilfrich, J.
Jackisch, C.
Witzel, I.
Eidtmann, H.
Bachinger, A.
Hell, S.
Blohmer, J.
ANNALS OF ONCOLOGY, 2013, 24 (03) : 618 - 624

← 1 2 3 4 5 →